



CLAIMS

1. A compound of formula (I):




being 4-(3-Fluoro-3-(2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethyl)pyrrolidin-1-yl)-3-(3-(2-methoxyethoxy) phenyl) butanoic acid, or a pharmaceutically acceptable salt thereof.


2. A compound of formula (I) as claimed in claim 1 having a formula selected from formula (IA1), (IA2), (IA3) or (IA4):




being (R)-4-((S)-3-Fluoro-3-(2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethyl)pyrrolidin-1-yl)-3-(3-(2-methoxyethoxy) phenyl) butanoic acid;



being (S)-4-((S)-3-Fluoro-3-(2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethyl)pyrrolidin-1-yl)-3-(3-(2-methoxyethoxy) phenyl) butanoic acid;




being (R)-4-((R)-3-Fluoro-3-(2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethyl)pyrrolidin-1-yl)-3-(3-(2-methoxyethoxy) phenyl) butanoic acid; and:



being (S)-4-((R)-3-Fluoro-3-(2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethyl)pyrrolidin-1-yl)-3-(3-(2-methoxyethoxy) phenyl) butanoic acid;
or a pharmaceutically acceptable salt thereof.

3. A compound of formula (I) as claimed in claim 1 having a formula



being (S)-4-((S)-3-Fluoro-3-(2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethyl)pyrrolidin-1-yl)-3-(3-(2-methoxyethoxy) phenyl) butanoic acid or a pharmaceutically acceptable salt thereof.

4. A compound of formula (I) as claimed in claim 1 which is (S)-4-((S)-3-Fluoro-3-(2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethyl)pyrrolidin-1-yl)-3-(3-(2-methoxyethoxy)phenyl)butanoic acid maleate salt.
5. A compound of formula (I) as claimed in claim 1 which is (S)-4-((S)-3-Fluoro-3-(2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethyl)pyrrolidin-1-yl)-3-(3-(2-methoxyethoxy)phenyl)butanoic acid citrate salt.
6. A compound of formula (I) according to any one of claims 1 to 5 or a pharmaceutically acceptable salt thereof for use in therapy.
7. Use of a compound of formula (I) according to any one of claims 1 to 5 or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of a fibrotic disease.
8. The use according to claim 7 wherein the fibrotic disease is a pulmonary fibrosis.
9. Use of a compound of formula (I) according to any one of claims 1 to 5 or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of a idiopathic pulmonary fibrosis.
10. A pharmaceutical composition comprising a compound of formula (I) according to any one of claims 1 to 5 or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable carriers, diluents or excipients.
11. A pharmaceutical composition according to claim 10 in a form adapted for oral administration.
12. A combination comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 5, and at least one other pharmaceutically active agent.
13. A combination according to claim 12, wherein an inhibitor of TGF β synthesis, for example pirfenidone, is the other pharmaceutically active agent.
14. A combination according to claim 12, wherein nintedanib (BIBF-1120) is the other pharmaceutically active agent.
15. A combination according to claim 12, wherein an anti $\alpha_v\beta_6$ antibody is the other pharmaceutically active agent.
16. A combination according to any one of claims 12-15, for use in therapy.